U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Science & Research
  3. Science and Research Special Topics
  4. Advancing Regulatory Science
  5. Focus Areas of Regulatory Science Report
  6. Focus Area: Technologies to Reduce Pathogen Contamination
  1. Focus Areas of Regulatory Science Report

Focus Area: Technologies to Reduce Pathogen Contamination

 

Scientist working in the laboratory, holding test tubes

Importance to FDA

A major public health safety concern is the risk of transmissible infectious diseases associated with the use of FDA-regulated medical products, consumption of food, or reuse or sharing of medical devices. In the medical product space, this is a challenge because many medical products cannot be terminally sterilized (meaning they’re sterilized in their final holding container) since some are composed of biological materials that may lose their ability to work as intended. Examples of biological materials include human blood and blood components, therapeutic proteins, monoclonal antibodies, live virus vaccines, certain gene therapy products, and cell-based therapies.

To address these issues, FDA encourages the development of tools designed to evaluate innovative technologies to reduce, inactivate, or eliminate pathogens from FDA-regulated products. The Agency combines typically used methods in conjunction with novel tool development to prevent transmission of infectious disease through FDA-regulated product use. Typical and novel methods incorporate one or more of the following:

  • Prevention, e.g., using carefully sourced raw materials; or
  • Reduction, inactivation, or elimination, e.g., irradiating devices and certain foods, terminally sterilizing drugs, removing, or inactivating methods applied to traditional biotechnology products or to certain foods; or
  • Detection, e.g., screening of the blood supply to remove units carrying human pathogens, sampling and testing foods and removing those containing foodborne pathogens from the marketplace.

Examples

  • FDA has regulatory oversight for the safety of human blood and tissues. The risk of transfusion-transmitted diseases in blood products has decreased significantly, and there continues to be low rates of transfusion-transmitted infectious diseases associated with the blood supply due to the development of specific assays for detection of known human pathogens and donor deferral policies. FDA evaluates and encourages development of simple and innovative technologies for effective pathogen reduction of whole blood and red blood cells and encourages improvement of existing technologies developed for platelets and plasma to continue improving the safety of the blood supply.
  • Investigating whether the application of nanopore technology makes it easier to detect and trace the Clostridium botulinum (C. botulinum) toxin and Escherichia coli (E. coli). New immune-based methods are being developed to enable rapid and sensitive detection of toxins in food substrates, such as C. botulinum, ricin, and abrin.
  • FDA has regulatory oversight for the safety of foods other than meat, poultry and processed egg products. FDA conducts research on the use of technologies such as high--pressure processing, non-thermal plasma, and thermal inactivation of pathogens in various food matrices. FDA also conducts research on new detection methods and the application of whole genome sequencing of microbial pathogens to identify outbreaks of illness and new sources of contamination and encourages industry to adopt new measures to control foodborne pathogens.
  • FDA has been working with industry to identify microbial contamination in tattoo inks and address ways to eliminate this problem. Some of these activities have included regulatory meetings to address issues of sterility and manufacturing processes, as well as working to identify the different types and quantity of microbes present in the inks using BAM chapter 23, USP 71 and are beginning to look at other methods to reduce time for testing.

 

 

CROSS-CUTTING TOPICS

Minority Health and Health Equity Women’s Health Maternal Health Pediatric Health
Oncology Rare Diseases One Health Initiative  

 

EXPLORE THE FOCUS AREAS OF REGULATORY SCIENCE

Advanced Manufacturing Antimicrobial Resistance Artificial Intelligence Biomarkers
Complex Innovative Trial Design Digital Health Technologies Empowering Patients and Consumers to Make Better-Informed Decisions Food Safety
Increasing Access to Complex Generic Drug Products Individualized Therapeutics and Precision Medicine Medical Countermeasures and Preparedness for Emerging Infectious Diseases Microbiome Research
Model-Informed Product Development Novel Foods and Food Ingredients Novel Technologies to Improve Predictivity of Non-clinical Studies and Replace, Reduce, and Refine Reliance on Animal Testing Patient and Consumer Preferences and Perspectives
Patient-Reported Outcomes and other Clinical Outcome Assessments Product Safety Surveillance Quality of Compounded Drugs Regenerative Medicine
  Substance Use Disorders Technologies to Reduce Pathogen Contamination Use of Real-World Evidence to Support Biologic, Device, and Drug Development and Regulatory Decision-Making

 

Research Capabilities, Tools, and Resources

Research Management and Collaborations Technology Transfer and Public-Private Partnerships Physical Standards and Reference Materials Intramural Grant Programs Extramural Funding Mechanisms

Scientific Education, Training, and Communication

Fellowship and Training Opportunities Professional Development and Continuing Education Communication and External Meetings

Infrastructure

Facilities and Shared Resources Safety and Compliance

 

ADDITIONAL ORGANIZATIONAL INFORMATION

Office of the Chief Scientist

Office of Regulatory Science and Innovation

 Contact Us: FARS@fda.hhs.gov

 

Back to Top